The use of progestin subdermal implants in the management of endometriosis-related pain symptoms and quality of life: a systematic review

References

• Wheeler JM. Epidemiology of endometriosis-associated infertility. J Reprod Med. 1989;34(1):41–46.
   PubMed Web of Science ®Google Scholar
• Singh S, Soliman AM, Rahal Y, et al. Prevalence, symptomatic burden, and diagnosis of endometriosis in Canada: cross-sectional survey of 30 000 women. J Obstet Gynaecol Can. 2020;42(7):829–838.
   PubMed Web of Science ®Google Scholar
• Levy AR, Osenenko KM, Lozano-Ortega G, et al. Economic burden of surgically confirmed endometriosis in Canada. J Obstet Gynaecol Can. 2011;33(8):830–837.
   PubMedGoogle Scholar
• Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20(10):2698–2704.
   PubMed Web of Science ®Google Scholar
• Brown J, Farquhar C. An overview of treatments for endometriosis. JAMA. 2015;313(3):296–297.
   PubMed Web of Science ®Google Scholar
• Kistner RW. Treatment of endometriosis by inducing pseudo- pregnancy with ovarian hormones. Fertil Steril. 1959;10(6):539–554.
   Web of Science ®Google Scholar
• Moghissi KS. Pseudopregnancy induced by estrogen- progestogen or progestogens alone in the treatment of endometriosis. Prog Clin Biol Res. 1990;323:221–232.
   PubMedGoogle Scholar
• Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol. 1996;175(2):396–401.
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20(7):1993–1998.
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95(2):492–496.
   PubMed Web of Science ®Google Scholar
• Andres MP, Lopes LA, Baracat EC, et al. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015;292(3):523–529.
   PubMed Web of Science ®Google Scholar
• Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107(3):533–536.
   PubMed Web of Science ®Google Scholar
• Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71(5):319–326.
   PubMed Web of Science ®Google Scholar
• Mansour D, Korver T, Marintcheva-Petrova M, et al. The effects of implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13 Suppl 1:13–28.
   PubMed Web of Science ®Google Scholar
• Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of implanon®. Contraception. 1998;58(6):99S–107S.
   PubMed Web of Science ®Google Scholar
• Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol. 2007;50(4):907–917.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, D’Alessandro G, et al. Etonogestrel-releasing contraceptive for the treatment of women with rectovaginal endometriosis: a pilot prospective study. Presented at the world congress of the royal college of obstetricians and gynaecologiests. 2019. 06 17-19; London, UK.
   Google Scholar
• Carvalho N, Margatho D, Cursino K, et al. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018;110(6):1129–1136.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Scala C, Ciccarelli S, et al. Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant. Gynecol Endocrinol. 2020;36(6):540–544.
   PubMed Web of Science ®Google Scholar
• Margatho D, Carvalho NM, Bahamondes L. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. Eur J Contracept Reprod Health Care. 2020;25(2):133–140.
   PubMed Web of Science ®Google Scholar
• Ng CHM, Fraser IS, Al Jefout MI, et al. Levonorgestrel intrauterine system combined simultaneously with an etonogestrel subdermal implant for refractory endometriosis-associated pelvic pain: an effective new therapy. Presented at the 2^nd asian conference on endometriosis. 2012. Istanbul, Turkey.
   Google Scholar
• Ponpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Thai. 2005;88(Suppl 2):S7–S10.
   PubMedGoogle Scholar
• Sansone A, Riccardi C, Cuomo L, et al. The effect of etonogestrel implant on endometriotic lesion: a pilot study. Presented at the 17^th ISGE world congress. 2016. Firenze, Italy.
   Google Scholar
• Sansone A, De Rosa N, Giampaolino P, et al. Effects of etonogestrel implant on quality of life, sexual function, and pelvic pain in women suffering from endometriosis: results from a multicenter, prospective, observational study. Arch Gynecol Obstet. 2018;298(4):731–736.
   PubMed Web of Science ®Google Scholar
• Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis-a pilot study. Contraception. 2009;79(1):29–34.
   PubMed Web of Science ®Google Scholar
• Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon)®. J Fam Plann Reprod Health Care. 2005;31(1):67–70.
   PubMedGoogle Scholar
• Ylanen K, Laatikainen T, Lahteenmaki P, et al. Subdermal progestin implant (nesterone ®) in the treatment of endometriosis: clinical response to various doses. Acta Obstet Gynecol Scand. 2003;82(2):167–172.
   PubMed Web of Science ®Google Scholar
• Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (implanon): results from 11 international clinical trials. Fertil Steril. 2009;91(5):1646–1653.
   PubMed Web of Science ®Google Scholar
• Buggio L, Somigliana E, Barbara G, et al. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. Expert Opin Pharmacother. 2017;18(15):1569–1581.
   PubMed Web of Science ®Google Scholar
• Wong AYK, Tang LCH, Chin RKH. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2010;50(3):273–279.
   PubMed Web of Science ®Google Scholar
• Grandi G, Barra F, Ferrero S, et al. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019;24(1):61–70.
   PubMed Web of Science ®Google Scholar
• Zigler R, McNicholas C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol. 2017;216(5):443–450.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Ramesh S, Chen M, et al. Progestin-only contraceptives effects on weight (review). Cochrane Database Syst Rev. 2016;(8):CD008815.
   PubMed Web of Science ®Google Scholar